ICMAR launch India’s first large-scale trial for two new TB vaccines – VPM1002 and Immuvac
The Indian Council of Medical Research (ICMR) has launched India’s first large-scale trial for two new TB vaccines – VPM1002 and Immuvac. The initiative would enroll 12,000 healthy household contacts of a patient whose sputum has tested positive for TB and are therefore at high risk of contracting the disease. VPM1002 is produced by the Serum Institute of India (Pune) & Immuvac is manufactured by Cadila Pharmaceuticals. These anti-Tuberculosis vaccines aim to prevent infection (pre-exposure) or prevent primary progression or reactivation of latent TB infection (post-exposure). According to the Global TB Report 2017 issued by the World Health Organization (WHO), India has the highest number of TB cases in the world.